CN113234142B - 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 - Google Patents

超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 Download PDF

Info

Publication number
CN113234142B
CN113234142B CN202110418890.8A CN202110418890A CN113234142B CN 113234142 B CN113234142 B CN 113234142B CN 202110418890 A CN202110418890 A CN 202110418890A CN 113234142 B CN113234142 B CN 113234142B
Authority
CN
China
Prior art keywords
ser
amino acid
leu
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110418890.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113234142A (zh
Inventor
李滢权
金圣根
朴荣燮
南效廷
金董植
朴在燦
尹桦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Institute for Biomedical Research
Original Assignee
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotechnology Research Institute filed Critical Mogam Biotechnology Research Institute
Priority to CN202110418890.8A priority Critical patent/CN113234142B/zh
Publication of CN113234142A publication Critical patent/CN113234142A/zh
Application granted granted Critical
Publication of CN113234142B publication Critical patent/CN113234142B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202110418890.8A 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 Active CN113234142B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110418890.8A CN113234142B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201280076586.9A CN104769113B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN202110418890.8A CN113234142B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
PCT/KR2012/006680 WO2014030780A1 (en) 2012-08-22 2012-08-22 Screening and engineering method of super-stable immunoglobulin variable domains and their uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280076586.9A Division CN104769113B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Publications (2)

Publication Number Publication Date
CN113234142A CN113234142A (zh) 2021-08-10
CN113234142B true CN113234142B (zh) 2024-03-05

Family

ID=50150075

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110418890.8A Active CN113234142B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN201280076586.9A Active CN104769113B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN201610833668.3A Active CN106986934B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201280076586.9A Active CN104769113B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN201610833668.3A Active CN106986934B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Country Status (6)

Country Link
US (1) US10078085B2 (cg-RX-API-DMAC7.html)
EP (2) EP2888367B1 (cg-RX-API-DMAC7.html)
JP (1) JP6073038B2 (cg-RX-API-DMAC7.html)
KR (2) KR101796689B1 (cg-RX-API-DMAC7.html)
CN (3) CN113234142B (cg-RX-API-DMAC7.html)
WO (1) WO2014030780A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234142B (zh) * 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
GB201419899D0 (en) 2014-11-07 2014-12-24 Univ Kent Canterbury Biopharmaceutical production method
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
KR101692629B1 (ko) * 2015-07-14 2017-01-03 계명대학교 산학협력단 매시브 플래카드 제어 장치 및 그 방법
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3452516A4 (en) * 2016-05-04 2019-11-27 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
WO2019066435A2 (ko) * 2017-09-29 2019-04-04 재단법인 목암생명과학연구소 Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
CN108893487A (zh) * 2018-07-19 2018-11-27 中国农业科学院北京畜牧兽医研究所 一种含有C-Myc蛋白融合标签的植物表达质粒载体及其载体的构建方法
AU2019408420B2 (en) * 2018-12-21 2025-04-17 Vib Vzw Fusion protein with a toxin and scaffold protein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662556A (zh) * 2002-05-22 2005-08-31 艾斯巴技术股份公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN1735630A (zh) * 2003-01-10 2006-02-15 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
CN104769113A (zh) * 2012-08-22 2015-07-08 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007784B1 (ko) 1993-07-02 1996-06-12 포항종합제철 주식회사 일산화탄소(co)가스 센서 및 그 제조방법
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP1137664A2 (en) * 1998-12-10 2001-10-04 Washington University Protein transduction system and methods of use thereof
EP1214352A2 (en) 1999-09-07 2002-06-19 Viventia Biotech Inc. Enhanced phage display libraries of human vh fragments and methods for producing same
ES2376454T3 (es) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
EP1644416A4 (en) 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
EP1786463A4 (en) * 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR
ES2377979T3 (es) * 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
US20070026012A1 (en) * 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
US9150850B2 (en) 2005-08-22 2015-10-06 Cornell Research Foundation, Inc. Compositions and methods for analyzing protein interactions
KR100981356B1 (ko) * 2006-01-31 2010-09-14 대한민국 신호서열 및 변이된 신호서열로 디자인된 분비증강자에의한 원래 형태의 수용성 재조합 단백질 생산 방법
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2008112640A2 (en) * 2007-03-09 2008-09-18 Sinomab Bioscience Limited Construction and use of a functionally human antibody library with maximized repertoire diversity
CA2691109A1 (en) 2007-06-18 2008-12-24 Kai Bao Tat signal peptides for producing proteins in prokaryotes
EP2238165B1 (en) 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-hiv domain antibodies and method of making and using same
RU2013139260A (ru) * 2011-01-28 2015-03-10 Нэшнл Рисеч Каунсил Оф Канада Конструирование иммуноглобулиновых доменов

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662556A (zh) * 2002-05-22 2005-08-31 艾斯巴技术股份公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN1735630A (zh) * 2003-01-10 2006-02-15 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
CN104769113A (zh) * 2012-08-22 2015-07-08 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN106986934A (zh) * 2012-08-22 2017-07-28 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Directed evolution of human heavy chain variable domain (VH) using in vivo protein fitness filter;Kim et al;PLOS ONE;第9卷(第6期);e98178 *
新型可溶性融合蛋白TAT-PEP对SD大鼠缺血性脑损伤的保护作用及相关机制研究;邓斌;中国博士学位论文全文数据库医药卫生科技辑(第02期);E066-14 *

Also Published As

Publication number Publication date
EP3165535A1 (en) 2017-05-10
US10078085B2 (en) 2018-09-18
US20160003844A1 (en) 2016-01-07
EP3165535B1 (en) 2019-05-15
JP2015531597A (ja) 2015-11-05
KR101796689B1 (ko) 2017-11-10
CN104769113A (zh) 2015-07-08
JP6073038B2 (ja) 2017-02-01
KR20150032337A (ko) 2015-03-25
KR101732552B1 (ko) 2017-05-08
CN104769113B (zh) 2017-10-31
CN113234142A (zh) 2021-08-10
CN106986934A (zh) 2017-07-28
EP2888367A1 (en) 2015-07-01
EP2888367A4 (en) 2016-04-20
CN106986934B (zh) 2021-09-14
WO2014030780A1 (en) 2014-02-27
KR20160072272A (ko) 2016-06-22
EP2888367B1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
CN106986934B (zh) 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
EP3288973B1 (en) Method for mass humanization of rabbit antibodies
JP2015531597A5 (cg-RX-API-DMAC7.html)
US10415033B2 (en) Phage-displayed single-chain variable fragment libraries and uses thereof
CN107513104A (zh) 免疫球蛋白结构域的工程改造
CN115536747B (zh) 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用
KR102216032B1 (ko) 합성 항체 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
HK40051447B (en) Screening and engineering method of super-stable immunoglobulin variable domains and their uses
HK40051447A (en) Screening and engineering method of super-stable immunoglobulin variable domains and their uses
CN112424221B (zh) 抗体文库和使用抗体文库的抗体筛选方法
Leow et al. Monoclonal IgY antibodies
JP6293829B2 (ja) 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
Bostrom et al. Design and construction of synthetic phage-displayed Fab libraries
Rajput et al. Phage-display technology for the production of recombinant monoclonal antibodies
Steven et al. In vitro maturation of a humanized shark VNAR domain to improve its biophysical properties
JP6974909B2 (ja) 減少したコンビナトリアル冗長性及び最適化ループ長分布を有するhc−cdr3のみのライブラリー
WO2022120024A1 (en) Variable heavy chain only libraries, methods of preparation thereof, and uses thereof
HK40039219B (en) Antibody library and antibody screening method using same
Salema et al. Advances in Antibody Phage Display-A review
Keklikian Construction of a Synthetic Human VL Phage Display Library and Isolation of Potential Neuropilin-1-specific VL Therapeutics from the Library

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051447

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Seoul, South Kerean

Patentee after: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Country or region after: Republic of Korea

Address before: Gyeonggi Do, South Korea

Patentee before: MOGAM BIOTECHNOLOGY Research Institute

Country or region before: Republic of Korea

EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210810

Assignee: GREEN CROSS Corp.

Assignor: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Contract record no.: X2025990000124

Denomination of invention: Screening and modification methods of ultra stable immunoglobulin variable domains and their applications

Granted publication date: 20240305

License type: Exclusive License

Record date: 20250327